Aurinia Pharmaceuticals Inc.

NASDAQ
AUPH
Stock
Yield per half year: -7.23%
Dividend yield: 0%
Sector: Healthcare

Share chart Aurinia Pharmaceuticals Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Aurinia Pharmaceuticals Inc.

Биофармацевтическая компания Aurinia Pharmaceuticals Inc. разрабатывает и коммерциализирует методы лечения различных заболеваний, при которых медицинские потребности не удовлетворяются в Японии и Китае. Компания предлагает ЛУПКИНИС для лечения взрослых пациентов с активным волчаночным нефритом. У нее есть соглашение о сотрудничестве и лицензионное соглашение с Otsuka Pharmaceutical Co., Ltd. Штаб-квартира компании находится в Виктории, Канада.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 1999-01-26
ISIN CA05156V1022
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Сайт link
Цена ао 8.08
Change price per day: 0% (8.08)
Change price per week: +0.1239% (8.07)
Change price per month: -0.2469% (8.1)
Change price per 3 month: +0.3727% (8.05)
Change price per half year: -7.23% (8.71)
Change price per year: +55.09% (5.21)
Change price per 3 year: -33.17% (12.09)
Change price per 5 year: -47.63% (15.43)
Change price per 10 year: +109.87% (3.85)
Change price per year to date: -9.72% (8.95)
All parameters

Grade

Underestimation
Title Value Grade
P/S 5.7 2
P/BV 3.55 5
P/E 233.07 1
EV/EBITDA 42.12 1
Total: 4.63
Efficiency
Title Value Grade
ROA, % 1.05 1
ROE, % 1.52 1
Total: 1.33
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA 2.5 5
Total: 7
Growth impulse
Title Value Grade
Yield Revenue, % 370.27 10
Yield Ebitda, % -131.29 0
Yield EPS, % -104.52 0
Total: 2
More

Insider trading

Main owners

Institutions Volume Share, %
Armistice Capital, LLC 12 8.59
Blackrock Inc. 9 6.07
NEA Management Company, LLC 4 2.78
State Street Corporation 3 1.94
Goldman Sachs Group Inc 2 1.51
Nuveen Asset Management, LLC 2 1.44
Tang Capital Management, LLC 2 1.44
Geode Capital Management, LLC 2 1.12
Vanguard Group Inc 2 1.07
Morgan Stanley 1 0.91

Contained in ETF

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.10135 426.34 0.8416
Principal Healthcare Innovators ETF 0.10135 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.02593 595.05 0.72598
iShares Morningstar Small-Cap ETF 0.02128 391.25 1.60498
iShares Morningstar Small-Cap Value ETF 0.01584 187.77 2.50476
0.05443.781.3

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Mr. Peter S. Greenleaf M.B.A. President, CEO & Director 1.34M 1970 (55 years)
Mr. Matthew Maxwell Donley M.B.A. Executive Vice President of Operations & Strategy 811.82k 1969 (56 years)
Mr. Stephen P. Robertson Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer 739.68k 1982 (43 years)
Mr. Michael R. Martin Chief Business Officer 350.57k 1972 (53 years)
Mr. Joseph M. Miller CPA Chief Financial Officer 791.92k 1974 (51 year)
Ms. Sue Evans Senior Vice President of Global Regulatory Affairs N/A
Mr. Scott Habig Chief Commercial Officer N/A 1960 (65 years)
Ms. Andrea Levin Christopher Head of the Corporate Communications & Investor Relations
Dr. Gregory F. Keenan M.D. Chief Medical Officer
Dr. Ann M. Daus Ph.D. Senior Vice President of Quality

About company

Address: Canada, Victoria, 4464 Markham Street - Open in google maps, Open in yandex maps
Website: https://www.auriniapharma.com